UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of January, 2019

Commission File Number: 001-38475

ASLAN PHARMACEUTICALS LIMITED

(Translation of registrant’s name into English)

ASLAN Pharmaceuticals Limited

83 Clemenceau Avenue

#12-03 UE Square

Singapore 239920

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  ☒             Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

Amendment to License Agreement

As previously disclosed, on May 12, 2014, we entered into a license agreement with CSL Limited (“CSL”), pursuant to which we obtained an exclusive, worldwide license to certain patents, know-how and other intellectual property owned or controlled by CSL related to CSL’s anti-IL13 receptor monoclonal antibody, CSL334, which we refer to as ASLAN004, and antigen binding fragments thereof. Under the agreement, we have the exclusive right to develop ASLAN004 products through clinical proof of concept for the treatment, diagnosis or prevention of diseases or conditions in humans.

On September 18, 2018, we amended the license agreement with CSL, primarily to change the focus of the development program from asthma to atopic dermatitis (the “Amendment”).

The foregoing description of the Amendment is not a complete description of all terms and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Exhibit 10.1

***Text Omitted and Filed Separately

with the Securities and Exchange Commission.

Confidential Treatment Requested

Under 17 C.F.R. Sections 200.80(c) and Rule 24b-2

AMENDMENT AGREEMENT No. 1 TO LICENCE AGREEMENT

BETWEEN

CSL LIMITED

ABN 99 051 588 348

AND

ASLAN Pharmaceuticals Pte Ltd

THIS AMENDMENT AGREEMENT No. 1 is made the        day of                    2018.

BETWEEN:

(hereinafter collectively referred to as the “Parties” and individually as a “Party”)

WHEREAS:

THEREFORE the Parties do hereby agree as follows:

means CSL’s proprietary anti-IL13Rα1 monoclonal antibody known as CSL334 which has the […***…] set out in Schedule 2, and any […***…] thereof, and includes any post translational modifications of such […***…] References in this Agreement to ASLAN004 are to be read as references to CSL334.

*** Confidential Treatment Requested

2

means Completion of clinical trials that support and immediately precede the initiation of a randomized, double blind placebo controlled study to determine the efficacy of […***…]

subject to the remainder of this clause, be on terms consistent with all of the terms of this Agreement, including with respect to payments due to CSL. In relation to any confidentiality obligations in a Sub-license agreement which relate solely to information not subject to obligations of confidence under a CSL Third Party Technology Agreement, ASLAN may agree for the duration of such obligations in the Sub-license agreement to be less than the duration specified in the first sentence of Section 16.3, provided that such duration must in all cases be at least […***…] from the date of disclosure of the relevant information by ASLAN;

ASLAN may disclose CSL’s Confidential Information to Third Parties for the purposes of the Licensing Program on a need to know basis, and who must be bound by similar obligations of confidentiality as contained in this Agreement, provided, however, that in relation to any confidentiality obligations which relate solely to information not subject to obligations of confidence under a CSL Third Party Technology Agreement, ASLAN may agree for the duration of such obligations to be less than the duration specified in the first sentence of Section 16.3, provided further that such duration must in all cases be at least […***…] from the date of disclosure of the relevant information by ASLAN;

Term of Confidentiality. The obligations of confidentiality set out in this Section 16 shall apply from the Effective Date until […***…] after the expiration or termination of this Agreement. In the case of information subject to obligations of confidence under a CSL Third Party Technology Agreement, such information shall be treated as confidential in accordance with the terms of the relevant CSL Third Party Technology Agreement.

[…***…]

*** Confidential Treatment Requested

3

[…***…]

[Signature page follows]

*** Confidential Treatment Requested

4

IN WITNESS WHEREOF, the Parties have executed this Amendment Agreement in duplicate originals by their duly authorised representative as of the date and year first above written.

Each person executing this Agreement on behalf of a Party represents and warrants his/ her capacity and authority to do so.

SCHEDULE 1

MASTER PLAN

[…***…]

*** Confidential Treatment Requested

6

[…***…]

*** Confidential Treatment Requested

7